To Determine the Effects of Deodorant, Antiperspirant and Washing on the Pharmacokinetics of 2% Testosterone MD Lotion
NCT ID: NCT00857168
Last Updated: 2009-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
36 participants
INTERVENTIONAL
2009-01-31
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will evaluate the impact of application of antiperspirant and deodorant on absorption of testosterone, when applied pre-application of Testosterone MD-Lotion® (cutaneous solution).
The study also aim to evaluate the impact of washing the application site on the absorption of testosterone, when washed post-application of Testosterone MD-Lotion® (cutaneous solution).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations
NCT00857961
Pharmacokinetics of Testosterone Lotion in the Treatment of Hypogonadal Males
NCT00372008
Testosterone MD-Lotion Residual Washing Study
NCT00996151
A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants
NCT01725451
A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations
NCT00702650
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Testosterone MD-Lotion
Group 2
Testosterone MD-Lotion
Group 3
Testosterone MD-Lotion
Group 4
Testosterone MD-Lotion
Group 5
Testosterone MD-Lotion
Group 6
Testosterone MD-Lotion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Testosterone MD-Lotion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Acrux DDS Pty Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Acrux Pharma Pty Ltd
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tina Soulis, PhD
Role: STUDY_DIRECTOR
Acrux Pharma Pty Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
QPharm Pty Ltd
Brisbane, Queensland, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MTE10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.